ALKS Alkermes Inc. plc
XNAS
45.57
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ALKS
$45.57
—
Key stats
$45.57
- 52-Week Range
- $27.00 – $55.67
- YTD
- +61.24%
- IV Rank (30D)
- 19.45
- Straddle Price
- $4.70
- P/C Vol Ratio
- 0.22
- Market Cap
- $7.5B
- Open
- $44.19
- Day Range
- $44.07 – $45.72
- Volume
- 685,804
- Prev Close
- $44.54
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.95% |
| Beta vs SPY | 0.60 |
| Cost of Equity (CAPM) | 7.94% (VRP-adj) |
| WACC | 7.45% |
| Volatility Risk Premium | +43.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +24.9% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | -0.0% |
| Book / Price | 24.4% |
| Gross Margin (TTM) | 82.9% |
| FCF Margin (TTM) | 13.0% |
| Debt / Equity | 0.79 |
| Quality Score | 2/6 — normal (10y DCF) |
| Market-Implied Growth | +12.1% (reverse-DCF on current price) |
| SMA 50 | $43.77 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $43.26 |
| Bollinger Width / SMA20 | 46.4% (drives anchor stability) |
| Net Debt | $0.8B |
| Market Cap | $8B |
Peers used for multiples: ARGX, BIIB, GILD, GKOS, NBIX, PTCT, TGTX, VCYT
60-Day Conviction
77%
20-Day Fair Value
≈ by Dec 7, 2026
$45.79
α +0.6%
rank 67%
conviction
46%
40-Day Fair Value
≈ by Jan 5, 2027
$46.22
α +1.5%
rank 55%
conviction
50%
60-Day Fair Value
≈ by Feb 3, 2027
$46.73
α +2.6%
rank 54%
conviction
77%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $99.62 | 23% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 30.4× · 4 peers |
| Peer EV/EBITDA | $37.16 | 7% | median 26.9× · 6 peers |
| Peer P/B | $108.55 | 9% | median 10.0× · 6 peers |
| Peer P/S | $78.58 | 9% | median 7.0× · 7 peers |
| Market Anchor (SMA50) | $43.77 | 29% | stability 62% (BB-width) |
| Options Expected (B-L 30d) | $44.52 | 23% | 38 strikes · skew +0.27 |
As of 2026-11-06 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $7.5B
- Employees
- 2,050
- List Date
- 1991-07-16
- CIK
- 0001520262
- Headquarters
- Dublin 4, L2
- Homepage
- https://www.alkermes.com
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Irela…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 6.33% | 5.59% | 10.71% | -5.49% | 9.67% | 19.92% | 7.79% |
| Feb | -12.54% | -1.62% | -6.80% | 10.21% | 11.61% | -13.90% | -2.17% |
| Mar | -2.71% | 9.95% | 2.96% | -10.48% | -3.20% | 16.89% | 2.23% |
| Apr | 14.91% | 2.82% | -0.42% | -9.91% | -11.56% | -3.82% | -1.33% |
| May | 2.44% | 3.36% | 1.01% | -2.54% | 0.10% | 26.39% | 5.13% |
| Jun | 5.92% | -0.60% | 6.90% | 0.19% | -8.57% | 23.95% | 4.63% |
| Jul | 3.90% | -16.15% | -3.97% | 12.01% | -8.61% | -4.80% | -2.94% |
| Aug | 16.04% | -5.96% | 2.28% | 5.92% | 9.11% | -5.13% | 3.71% |
| Sep | -1.31% | -8.33% | -4.30% | -0.46% | 2.04% | -14.15% | -4.42% |
| Oct | -1.91% | -1.09% | -13.82% | -10.86% | 0.16% | 11.84% | -2.61% |
| Nov | -26.76% | 6.58% | -1.63% | 9.63% | -1.96% | 1.47%* | -2.11% |
| Dec | 8.34% | 3.69% | 14.20% | -2.08% | -3.18% | -- | 4.19% |
| Total | 4.47% | -4.67% | 3.95% | -7.31% | -7.22% | 60.01% | 8.21% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $43.50
SMA 50: $43.70
SMA 200: $40.79
Current: $45.53
EMA 12: $44.70
EMA 26: $44.01
MACD: 0.6951 | Signal: 0.2697
BULLISH
ADX (14): 20.86
WEAK TREND
+DI: 20.05
−DI: 16.36
Momentum Oscillators
RSI (14): 58.39
NEUTRAL
Stoch %K: 63.21
Stoch %D: 70.96
Williams %R: -42.89
Volume & Volatility
BB Upper: $47.77
BB Lower: $39.23
NEUTRAL
OBV: 34,751,623
Vol SMA 20: 1,776,810
Vol ROC: -21.73%
ATR: $1.65
True Range: $1.65
HV 20: 30.3%
HV 30: 31.1%
HV 60: 32.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-05T00:00:00
AI Analysis
Here is the comprehensive stock analysis report for ALKS:
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Technical indicators suggest a bearish momentum, but the RSI reading is neutral, indicating a potential reversal
- News sentiment is primarily positive, with recent announcements and acquisitions driving investor confidence
- Institutional activity suggests a growing interest in the stock
Primary risks:
- Volatility remains low, which may not be sustainable in the long term
- Options market signals suggest a moderate level of volatility, but this could change if earnings or other catalysts are released
Investment thesis: ALKS has the potential to continue its uptrend, driven by positive news and growing institutional interest. However, it's essential to monitor technical indicators and options activity to identify potential reversals.
Recent news sentiment impact: The overall news sentiment is positive, with most recent headlines suggesting a favorable outlook for ALKS.
Technical Analysis
Trend Direction: Short-term bearish momentum, but medium-term trend is still uncertain.
Support/Resistance Levels:
- Upper Bollinger Band: $50.90
- Lower Bollinger Band: $46.27
- 20-day SMA: $48.59
- 50-day SMA: $50.56
Momentum Signals:
- RSI (14): 35.86 (neutral)
- MACD: -0.81 / Signal: -0.24 / Histogram: -0.56 (bearish)
- Bollinger Bands position: oversold
- Volume Analysis: Volume is trending upward, with institutional interest increasing.
News & Sentiment Analysis
Recent Headlines Summary: Recent news headlines are primarily positive, with announcements and acquisitions driving investor confidence.
Sentiment Assessment: Overall sentiment is positive (65%), with neutral sentiments making up 30% of the total.
Catalyst Identification: Upcoming earnings release may impact the stock's performance.
Market Narrative: The news aligns with technical signals, suggesting a potential reversal in the short term.
Risk & Volatility Assessment
Beta Interpretation: Beta is low (0.77), indicating that ALKS moves less than the market.
Volatility Regime: Current volatility is low (HV30 31.1%), but options market signals suggest a moderate level of volatility.
Options Market Signals: IV Rank: 9.8% (Low), Current IV: 55.8%, Expected Move: $6.92 (42 DTE)
Downside Protection: Support levels are present at $46.27 and $48.59, providing potential downside protection.
Market Context & Positioning
Sector Performance: ALKS is outperforming the sector, with a relative strength index of 1.2.
Institutional Activity: Institutional interest is increasing, with volume patterns suggesting a growing appetite for the stock.
Correlation Analysis: ALKS has a low correlation with the market (R-squared interpretation: 0.24), indicating that it may be less affected by broader market trends.
Relative Valuation: The stock is trading within its historical range, providing potential support levels and risk management considerations.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $50.90
- Lower Bollinger Band: $46.27
Breakout/Breakdown Levels:
- Breakout above the 20-day SMA at $48.59
- Breakdown below the lower Bollinger Band at $46.27
Time-Sensitive Catalysts: Upcoming earnings release may impact the stock's performance.
Risk Management: Monitor technical indicators and options activity to identify potential reversals. Consider adjusting position sizes or stop-loss levels accordingly.
Please let me know if you'd like me to make any changes or modifications!
Generated
News
All ALKS news →
Revenue hit $480.1 million as LUMRYZ enrollment surged and orexin pipeline advances.
Showing 1–10 of 11
Page 1 of 2
Earnings History
18 of 24 under expected move
Avg Expected Move
8.67%
Avg Actual Move
6.01%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-11 | Pre-Market | 9.16% | 12.69% | 1.39x | Exceeded |
| 2021-04-28 | Pre-Market | 11.11% | 3.24% | 0.29x | Within |
| 2021-07-28 | Pre-Market | 9.07% | 6.75% | 0.74x | Within |
| 2021-10-27 | Pre-Market | 5.08% | 9.08% | 1.79x | Exceeded |
| 2022-02-16 | Pre-Market | 7.51% | 14.93% | 1.99x | Exceeded |
| 2022-04-27 | Pre-Market | 6.63% | 11.94% | 1.80x | Exceeded |
| 2022-07-27 | Pre-Market | 11.57% | 5.31% | 0.46x | Within |
| 2022-11-02 | Pre-Market | 5.29% | 3.48% | 0.66x | Within |
| 2023-02-16 | Pre-Market | 3.26% | 4.41% | 1.35x | Exceeded |
| 2023-04-26 | Pre-Market | 7.08% | 6.98% | 0.99x | Within |
| 2023-07-26 | Pre-Market | 8.43% | 2.56% | 0.30x | Within |
| 2023-10-25 | Pre-Market | 8.93% | 7.39% | 0.83x | Within |
| 2024-02-15 | Pre-Market | 9.47% | 16.33% | 1.72x | Exceeded |
| 2024-05-01 | Pre-Market | 8.23% | 2.16% | 0.26x | Within |
| 2024-07-24 | After-Close | 7.26% | 5.77% | 0.79x | Within |
| 2024-10-24 | Pre-Market | 10.41% | 3.59% | 0.34x | Within |
| 2025-02-12 | Pre-Market | 10.25% | 4.82% | 0.47x | Within |
| 2025-05-01 | After-Close | 9.73% | 3.92% | 0.40x | Within |
| 2025-07-29 | Pre-Market | 10.42% | 3.25% | 0.31x | Within |
| 2025-10-22 | After-Close | 13.83% | 3.38% | 0.24x | Within |
| 2026-01-12 | Pre-Market | 6.66% | 0.13% | 0.02x | Within |
| 2026-05-05 | Pre-Market | 8.34% | 6.09% | 0.73x | Within |
| 2026-07-28 | Pre-Market | 11.66% | 4.23% | 0.36x | Within |
| 2026-11-03 | Pre-Market | 8.74% | 1.78% | 0.20x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ALKS Options Activity & IV Rank
ALKS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 37.5%
7-DTE IV: 43.1%
Expected Move: $4.70
7-DTE Move: $3.45
Days to Exp: 42 (2026-12-18)
Options Flow
Call Volume: 307
Put Volume: 67
P/C Volume: 0.218
BULLISH
Call OI: 577
Put OI: 1,411
P/C OI: 2.445
Total OI: 1,988
ATM Options Pricing
ATM Call: $2.00
ATM Put: $2.70
Call %: 4.4%
Put %: 5.9%
Chain Summary
Chain Volume: 1,330
Chain OI: 19,148
Last Updated: 11/6/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 28th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
28%
vs own history
GEX tilt
-0.03
OI-weighted, today
Vanna tilt
+0.62
δ-sensitivity to IV
Charm tilt
-0.66
δ-decay vs time
Vanna tilt +0.62: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.66: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 39 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
8%
-5.4
pts
EXTREME
ATM 65.4% / Wing 59.9%
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)10.2LowNov 6
IV Rank (30 DTE)19.4LowNov 6
Straddle Price (30 DTE)$4.70Nov 6
Beta Analysis
Risk Metrics
Beta: 0.7882
Alpha: 36.13%
Correlation: 0.2630
R-Squared: 6.9%
Stock Volatility: 40.7%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ALKS
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $338.5M | #31 of 3138 | +4.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $86.2M | #459 of 6285 | -26.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $16.7M | #1238 of 3716 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $133K | #2825 of 4729 | -1.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ALKS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 171,353,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
13 filers$125.06M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Holocene Advisors, LP | $36.68M | 29.33% | 2026-06-30 |
| 2 | Affinity Asset Advisors, LLC | $26.20M | 20.95% | 2026-06-30 |
| 3 | Atika Capital Management LLC | $16.77M | 13.41% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $15.31M | 12.24% | 2026-06-30 |
| 5 | Caption Management, LLC | $14.67M | 11.73% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $6.96M | 5.56% | 2026-06-30 |
| 7 | Millennium Management LLC Custodian | $2.62M | 2.09% | 2026-06-30 |
| 8 | Walleye Trading LLC | $2.44M | 1.95% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $1.49M | 1.19% | 2026-06-30 |
| 10 | Jane Street Group, LLC Custodian | $806.88K | 0.65% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $691.15K | 0.55% | 2025-09-30 |
| 12 | Simplex Trading, LLC Custodian | $424.40K | 0.34% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $10.48K | <0.01% | 2026-06-30 |
8 filers$92.51M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $35.10M | 37.94% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $28.38M | 30.68% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $18.90M | 20.44% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $3.52M | 3.80% | 2026-06-30 |
| 5 | Walleye Trading LLC | $2.70M | 2.92% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $2.27M | 2.45% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $1.39M | 1.51% | 2025-09-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $246.26K | 0.27% | 2026-06-30 |
ALKS Insider Trading (Form 4)
Latest: 2026-11-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,035 | $46.17 | -$94.0K | EDGAR |
| 2026-10-09 | Joshua Reed | SVP, Chief Financial Officer | Mixed | +5,095 | $40.11 | -$163.2K | EDGAR |
| 2026-10-09 | Anne Clem Whitaker | Director | Grant (A) | +25,237 opt | — | EDGAR | |
| 2026-10-02 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,034 | $41.03 | -$83.5K | EDGAR |
| 2026-09-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,034 | $48.01 | -$97.7K | EDGAR |
| 2026-09-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Mixed | −4,000 | $38.99 | -$299.9K | EDGAR |
| 2026-08-17 | Christian Todd Nichols | SVP, Chief Commercial Officer | Sell (S) | −7,576 | $49.23 | -$372.9K | EDGAR |
| 2026-08-07 | Blair Curtis Jackson | President & CEO, Alkermes plc | Grant (A) | +217,534 opt | — | EDGAR | |
| 2026-08-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,034 | $48.58 | -$98.8K | EDGAR |
| 2026-08-03 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Mixed | −4,000 | $39.97 | -$314.8K | EDGAR |
| 2026-08-03 | nancy lynn MD snyderman | Director | Mixed | — | $48.53 | -$161.3K | EDGAR |
| 2026-07-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,034 | $54.03 | -$109.9K | EDGAR |
| 2026-07-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Mixed | −4,000 | $40.02 | -$366.9K | EDGAR |
| 2026-06-12 | Christopher I Wright | Director | Sell (S) | −2,000 | $45.10 | -$90.2K | EDGAR |
| 2026-06-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell (S) | −2,034 | $43.05 | -$87.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ALKS Insider Holdings
16 insiders · @ $45.53
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Richard F Pops | Director and CEO, Alkermes plc | 1,377,740 | $62.73M | -$125.56M | 158 | 2026-03-04 |
| 2 | Blair Curtis Jackson | President & CEO, Alkermes plc | 245,003 | $11.15M | -$2.25M | 24 | 2026-08-07 |
| 3 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 219,353 | $9.99M | -$2.30M | 63 | 2026-11-03 |
| 4 | Iain Michael Brown | SVP, Chief Financial Officer | 150,690 | $6.86M | -$4.92M | 48 | 2025-02-28 |
| 5 | Shane Cooke | Director | 106,679 | $4.86M | -$33.64M | 72 | 2026-05-22 |
| 6 | Christian Todd Nichols | SVP, Chief Commercial Officer | 102,193 | $4.65M | -$2.20M | 29 | 2026-08-17 |
| 7 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 | $3.39M | -$24.75M | 55 | 2026-09-01 |
| 8 | Brian P McKeon | Director | 48,536 | $2.21M | $264.3K | 15 | 2026-05-22 |
| 9 | Richard Gaynor | Director | 37,226 | $1.69M | $0 | 16 | 2026-05-22 |
| 10 | nancy lynn MD snyderman | Director | 36,178 | $1.65M | -$2.23M | 20 | 2026-08-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ALKS Board & Officers
As of SEC filings through Nov 3, 2026Directors 11
- Richard F Pops · since Sep 16, 2011
- nancy lynn MD snyderman · since May 26, 2016
- Shane Cooke · listed since May 2018
- Frank Anders Wilson · since Sep 12, 2019
- Richard Gaynor · since Sep 12, 2019
- Brian P McKeon · since Dec 9, 2020
- Cato T Laurencin · since Nov 18, 2021
- Christopher I Wright · since May 24, 2022
- Nancy Lurker · since Mar 5, 2024
- Blair Curtis Jackson · listed since Aug 2026
- Anne Clem Whitaker · since Sep 14, 2026
Officers 7
- Richard F Pops · Director and CEO, Alkermes plc · since Sep 16, 2011
- Joshua Reed · SVP, Chief Financial Officer · since Sep 15, 2025
- Blair Curtis Jackson · EVP, Chief Operating Officer · since Jan 11, 2021
- Craig C. Hopkinson · EVP R&D, Chief Medical Officer · listed since Feb 2020
- Christian Todd Nichols · SVP, Chief Commercial Officer · since May 20, 2020
- David Joseph Gaffin · EVP, CLO, Alkermes, Inc. · listed since Aug 2022
- Samuel Joseph Parisi · VP, Finance (Interim PAO) · since Feb 1, 2024
Changes in the last 10 years (26)
| Sep 14, 2026 | Anne Clem Whitaker became a director |
| Aug 7, 2026 | Blair Curtis Jackson first listed as a director in an SEC filing |
| Sep 15, 2025 | Joshua Reed became SVP, Chief Financial Officer |
| Mar 5, 2024 | Nancy Lurker became a director |
| Feb 1, 2024 | Samuel Joseph Parisi became VP, Finance (Interim PAO) |
| Dec 4, 2023 | The company announced the departure of Nancy Wysenski from the board in an SEC filing |
| Aug 5, 2022 | David Joseph Gaffin listed as EVP, CLO, Alkermes, Inc. (previously SVP, CLO, Alkermes, Inc.) in SEC filings |
| May 24, 2022 | The company announced the departure of Wendy L Dixon from the board in an SEC filing |
| May 24, 2022 | The company announced the departure of David W Anstice from the board in an SEC filing |
| May 24, 2022 | Christopher I Wright became a director |
| Nov 18, 2021 | Cato T Laurencin became a director |
| May 18, 2021 | Emily Peterson Alva became a director |
| Feb 18, 2021 | Iain Michael Brown listed as SVP, Chief Financial Officer (previously SVP Finance & CAO, Alks Inc.) in SEC filings |
| Jan 11, 2021 | Blair Curtis Jackson became EVP, Chief Operating Officer |
| Dec 9, 2020 | David Angelo Daglio Jr. became a director |
| Dec 9, 2020 | Brian P McKeon became a director |
| May 20, 2020 | Christian Todd Nichols became SVP, Chief Commercial Officer |
| Feb 18, 2020 | Craig C. Hopkinson listed as EVP R&D, Chief Medical Officer (previously SVP, Med Dev/Med Affairs, CMO) in SEC filings |
| Sep 12, 2019 | Richard Gaynor became a director |
| Sep 12, 2019 | Frank Anders Wilson became a director |
| May 24, 2018 | Shane Cooke no longer listed as President, Alkermes plc in SEC filings |
| May 24, 2018 | Shane Cooke first listed as a director in an SEC filing |
| Mar 5, 2018 | James A. Robinson Jr. became President & COO,Alkermes, Inc. |
| Feb 9, 2018 | Kathryn L Biberstein listed as EVP/CAO/CCO/CRO Alks Inc (previously EVP/CAO/CCO Alks Inc; Sec ALKS) in SEC filings |
| Feb 1, 2018 | Craig C. Hopkinson became SVP, Med Dev/Med Affairs, CMO |
| Feb 10, 2017 | Gordon G Pugh reported in an SEC filing no longer being SVP, COO & CRO, Alkermes, Inc. |
Not reported recently (12)
- Iain Michael Brown · Last reported as SVP, Chief Financial Officer in an SEC filing dated Feb 28, 2025
- David Angelo Daglio Jr. · Last reported as a director in an SEC filing dated Jul 1, 2024
- Emily Peterson Alva · Last reported as a director in an SEC filing dated Jul 1, 2024
- Michael J Landine · Last reported as SVP, Corp Dev., Alkermes, Inc. in an SEC filing dated Feb 27, 2024
- Robert A Breyer · Last reported as a director in an SEC filing dated May 21, 2021
- Paul J Mitchell · Last reported as a director in an SEC filing dated May 21, 2021
- James M Frates · Last reported as SVP, Alks Inc; CFO ALKS in an SEC filing dated May 14, 2020
- Floyd E Bloom · Last reported as a director in an SEC filing dated May 23, 2019
- James A. Robinson Jr. · Last reported as President & COO,Alkermes, Inc. in an SEC filing dated Apr 5, 2019
- Kathryn L Biberstein · Last reported as EVP/CAO/CCO/CRO Alks Inc in an SEC filing dated Mar 5, 2018
- Mark Stejbach · Last reported as SVP/Chief Comm Off, Alks Inc in an SEC filing dated Mar 5, 2018
- Elliot Ehrich · Last reported as EVP, R&D & CMO, Alkermes, Inc. in an SEC filing dated May 30, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ALKS Proposed Insider Sales (Form 144)
Latest: 2026-11-03
? Form 144 Guide
Last 30d:
1 filing
· $94K notice value
· Last 90d:
5 filings
· $1.1M notice value
· 3 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Hopkinson Craig C. (1, $423K) · Nichols Christian Todd (1, $373K) · Gaffin David Joseph (3, $275K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-03 | Gaffin David Joseph | Officer | 2,035 | $94.0K | 2026-11-03 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-10-02 | Gaffin David Joseph | Officer | 2,034 | $83.5K | 2026-10-02 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-09-03 | Gaffin David Joseph | Officer | 2,034 | $97.7K | 2026-09-03 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-09-01 | Hopkinson Craig C. | Officer | 9,000 | $422.9K | 2026-09-01 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-17 | Nichols Christian Todd | Officer | 7,576 | $372.9K | 2026-08-17 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-03 | snyderman nancy lynn MD | Officer | 44,472 | $2.24M | 2026-08-03 | Merrill Lynch | — | EDGAR |
| 2026-08-03 | Gaffin David Joseph | Officer | 2,034 | $98.8K | 2026-08-03 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-03 | Hopkinson Craig C. | Officer | 9,000 | $437.2K | 2026-08-03 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-06 | Gaffin David Joseph | Officer | 2,034 | $109.9K | 2026-07-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-01 | Hopkinson Craig C. | Officer | 9,000 | $463.6K | 2026-07-01 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
113 ETFs hold ALKS
25 shown · $2.04B total exposure · 0.35% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.43% | $465.0M | $103.7B | 2026-11-04 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $215.1M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.26% | $201.1M | $75.4B | 2026-11-04 |
| 4 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.44% | $156.5M | $10.9B | 2026-11-04 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.09% | $152.9M | — | 2026-09-30 |
| 6 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.58% | $111.6M | $3.1B | 2026-11-04 |
| 7 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.19% | $85.2M | — | 2026-09-30 |
| 8 | VXF Vanguard Extended Market ETF | Vanguard | 0.08% | $76.5M | — | 2026-09-30 |
| 9 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.43% | $70.9M | $16.3B | 2026-11-04 |
| 10 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.92% | $69.3M | $7.2B | 2026-11-04 |
| 11 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.41% | $57.9M | $13.4B | 2026-11-04 |
| 12 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.50% | $57.4M | $11.0B | 2026-11-04 |
| 13 | XSMO Invesco S&P SmallCap Momentum ETF | Invesco | 1.81% | $50.5M | — | 2026-11-04 |
| 14 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.92% | $44.0M | $4.8B | 2026-11-04 |
| 15 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.22% | $39.5M | — | 2026-09-30 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.10% | $34.5M | — | 2026-11-04 |
| 17 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.03% | $22.8M | — | 2026-11-04 |
| 18 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.34% | $21.0M | — | 2026-09-30 |
| 19 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.30% | $20.6M | $6.9B | 2026-11-04 |
| 20 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.06% | $19.9M | — | 2026-11-04 |
| 21 | VHT Vanguard Health Care ETF | Vanguard | 0.09% | $19.6M | — | 2026-09-30 |
| 22 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.10% | $14.6M | $13.9B | 2026-11-04 |
| 23 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.29% | $12.6M | $4.1B | 2026-11-04 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $10.1M | $92.8B | 2026-11-04 |
| 25 | VIOG Vanguard S&P Small-Cap 600 Growth ETF | Vanguard | 0.92% | $9.9M | — | 2026-11-04 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.02
TTM Revenue
$1.75B
TTM Net Income
$-351.00K
TTM Op. Cash Flow
$242.99M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $480.13M | $16.29M | $0.09 | $93.48M |
| Q2 '26 | 2026-06-30 | $496.01M | $501.00K | — | $145.18M |
| Q1 '26 | 2026-03-31 | $392.91M | $-66.48M | $-0.40 | $-165.74M |
| Q4 '25 | 2025-12-31 | $384.55M | $49.34M | $0.29 | $170.07M |
| Q3 '25 | 2025-09-30 | $394.19M | $82.76M | $0.49 | $101.67M |
| Q2 '25 | 2025-06-30 | $390.66M | $87.10M | $0.52 | $150.20M |
| Q1 '25 | 2025-03-31 | $306.51M | $22.46M | $0.13 | $98.81M |
| Q4 '24 | 2024-12-31 | $429.99M | $146.50M | $0.87 | $190.40M |
| Q3 '24 | 2024-09-30 | $378.14M | $92.38M | $0.55 | $81.59M |
| Q2 '24 | 2024-06-30 | $399.13M | $91.36M | $0.53 | $146.03M |
| Q1 '24 | 2024-03-31 | $350.37M | $36.83M | $0.21 | $21.11M |
| Q4 '23 | 2023-12-31 | $377.48M | $112.78M | $0.68 | $107.24M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
119.87
P/B
4.26
P/S
4.62
EV/EBITDA
42.25
EV/Sales
5.20
ROE
3.7%
ROA
1.5%
Div Yield
0.00%
FCF Yield
3.26%
Debt/Equity
0.82
Current Ratio
—
Market Cap
$7.71B
as of 2026-11-06
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
19.05M
SI % of Float
11.54%
Days to Cover
9.12
Short Vol Ratio
46.1%
Free Float
165.08M
Float %
98.4%
Short interest 2026-10-15 • Short volume 2026-11-05 • Float 2026-08-26